Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: fixed dose combination therapies - Celator

Drug Profile

Research programme: fixed dose combination therapies - Celator

Alternative Names: AUY 922/docetaxel - Celator Pharma; CPX-571; Docetaxel/luminespib - Celator Pharma; Ipatasertib/selumetinib - Celator Pharma; Targeted cancer therapies: Celator Pharma

Latest Information Update: 02 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Celator Pharmaceuticals
  • Class
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Apoptosis modulators; DNA cross linking agents; DNA synthesis inhibitors; DNA topoisomerase I inhibitors; Extracellular signal-regulated MAP kinase inhibitors; Histone acetyltransferase inhibitors; Histone deacetylase inhibitors; Mitogen-activated protein kinase kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors; Raf kinase inhibitors; Ras protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • No development reported Cancer; Head and neck cancer; Lung cancer

Most Recent Events

  • 30 Jul 2019 Array Biopharma has been acquired by Pfizer
  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 28 Aug 2018 No recent reports of development identified for research development in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top